Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation.
| Date | Est. | Actual | |
|---|---|---|---|
| May 20, 2026 | -$0.40 | -$0.03 | Beat |
| Jan 13, 2026 | -$0.40 | -$0.11 | Beat |
| Aug 14, 2025 | -$0.40 | -$0.55 | Miss |
| May 15, 2025 | -$0.38 | -$0.40 | Miss |
| Mar 28, 2025 | -$0.37 | -$2.62 | Miss |
| Nov 15, 2024 | -$1.02 | -$0.70 | Beat |